Search the Newsreel

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript

COMPASS Pathways reported its Q2 2026 earnings, detailing a net loss of $253.8 million, increased G&A expenses, and $433.3 million in cash and cash equivalents expected to fund operations into 2028. The company is on track to submit the final modules of its New …

CMPS: COMP360 targets a 2027 launch, offering rapid, durable relief for TRD and advancing a PTSD program

COMPASS Pathways' product, COMP360, is aiming for a 2027 launch after a Q4 NDA filing, FDA review, and DEA rescheduling. It promises rapid and lasting relief for treatment-resistant depression with a good safety profile and high payer interest. The company is also advancing a …

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Compass Pathways PLC (NASDAQ:CMPS) has received a "Moderate Buy" consensus rating from seventeen brokerages, with an average 12-month price target of $23.36, significantly higher than its current share price of $13.38. While some analysts maintained or raised price targets, HC Wainwright lowered its target …

HC Wainwright Cuts Earnings Estimates for Compass Pathways

COMPASS Pathways (CMPS) insider files Form 144 for 26,000 ADS sale

A COMPASS Pathways plc (CMPS) insider has filed a Form 144 to sell 26,000 American Depositary Shares (ADS) through Fidelity Brokerage Services LLC on August 10, 2026. This proposed sale, with an aggregate market value of $345,799.36, follows a stock option exercise by the …

COMPASS Pathways (CMPS) Joins VA PIVOT Trial, Is The Stock Still Cheap?

COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run

COMPASS Pathways (CMPS) has seen a significant 214.4% stock gain over the past year, but its current valuation, particularly its Price-to-Book (P/B) ratio of 21.6x, suggests it may be overvalued compared to the biotech industry average. Despite its strong performance, the company's loss-making profile …

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways is collaborating with the U.S. Department of Veterans Affairs (VA) on a multi-site clinical trial to assess the safety and efficacy of COMP360 psilocybin for treating treatment-resistant depression (TRD) in veterans, including those with co-occurring post-traumatic stress disorder (PTSD). The study, named …

COMPASS Pathways plc SEC Filing (Aug 7, 2026)

This article reports on a Form 144 SEC filing by COMPASS Pathways plc (CMPS) dated August 7, 2026. The filing indicates a proposed sale of 83,771 American Depositary Shares, acquired through a stock option exercise on the same date, with an aggregate market value …

Compass Pathways PLC (CMPS) Stock News Today

Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS

Renaissance Technologies LLC decreased its stake in Compass Pathways PLC by 10.6% in the first quarter of 2026, selling 102,492 shares but still retaining 865,354 shares valued at $4.8 million. Despite this reduction, other institutional investors increased their positions, and analysts generally maintain a …

COMPASS Pathways (NasdaqGS:CMPS) Stock Forecast & Analyst Predictions

COMPASS Pathways (CMPS) is forecast to grow earnings and revenue significantly, with analysts predicting a 56.4% earnings growth rate and 67.5% revenue growth rate annually. The company's lead asset, COMP360 psilocybin treatment, has shown promising Phase 3 trial results for treatment-resistant depression (TRD) and …

ETFs Investing in COMPASS Pathways Plc Sponsored ADR Stocks

This article lists various ETFs that hold COMPASS Pathways Plc Sponsored ADR stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and performance metrics. The list is sorted by market value and aims to make investing in these …

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways plc (Nasdaq: CMPS) announced its participation in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, where management will hold a fireside chat. Additionally, the company will attend the Stifel Biotech Summit on August 10, 2026. Both events will have live …

Compass Pathways partners with VA on psilocybin trial for veterans

Compass Pathways is collaborating with the U.S. Department of Veterans Affairs on a multi-site clinical trial for their COMP360 psilocybin treatment for veterans with treatment-resistant depression, including those with PTSD. The "PIVOT" study will evaluate different doses of COMP360, a synthetic psilocybin formulation, across …

CEO Kabir Nath has shares withheld for taxes at COMPASS Pathways (CMPS)

COMPASS Pathways CEO Kabir Nath reported an insider transaction where 5,962 Ordinary Shares were withheld by the issuer on August 3, 2026, to cover tax withholding obligations upon the vesting of restricted share units. These shares were valued at $11.25 per share and were …

Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips

COMPASS Pathways reported $433 million in cash as of June 30, sufficient to fund operations through launch and into 2028, and is progressing with its NDA submission for COMP360, a psilocybin treatment for depression. Despite positive Phase III data and advancing commercial preparations, the …

RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating

RBC has revised its price target for COMPASS Pathways (CMPS) down to $21 from $22, while continuing to maintain an "Outperform Speculative Risk" rating on the stock. This adjustment comes amidst recent news for the biotechnology company, including other analyst rating changes and financial …

B. Riley Financial Forecasts Strong Price Appreciation for Compass Pathways (NASDAQ:CMPS) Stock

Compass Pathways (Nasdaq: CMPS) grows cash to $433M as COMP360 trials succeed

Compass Pathways plc reported a net loss of $162.6 million for the first six months of 2026, largely due to non-cash warrant liabilities and increased administrative spending, yet saw its cash and cash equivalents grow to $433.3 million. This financial boost was driven by …

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK, August 05, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen …

Oppenheimer reiterates Compass Pathways stock rating on FDA progress By Investing.com

Oppenheimer has reaffirmed its Outperform rating and $20.00 price target for Compass Pathways (NASDAQ:CMPS) following the company's Q2 2026 update, which bolstered confidence in its psilocybin-based therapy, COMP360. Compass Pathways holds $433 million in cash, providing runway into 2028, and is progressing towards potential …

Compass Pathways (NASDAQ:CMPS) Announces Earnings Results, Misses Expectations By $1.49 EPS

COMPASS Pathways Q2 2026 Loss Widens 358.5% Beyond Estimates

COMPASS Pathways plc (NASDAQ:CMPS) reported a Q2 2026 loss of $1.88 per share, significantly wider than the estimated $0.41, representing a 358.5% miss. Despite the substantial net loss of $253.8M, the stock rallied 4.9%, indicating investor focus on clinical development milestones over immediate financial …

COMPASS Pathways (CMPS) Is Up 8.8% After Q2 Net Loss Surges To US$254 Million – Has The Bull Case Changed?

COMPASS Pathways reported a significant net loss of US$253.79 million in Q2 2026, a sharp increase from the previous year, with losses per share at US$1.88. This surge in expenses comes as the company remains pre-revenue, intensifying focus on its ability to fund the …

COMPASS PATHWAYS ($CMPS) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Cash Position: $433 million in cash on hand as of June 30, 2026, expected to fund operations through launch and into 2028. Regulatory Milestone: Rolling NDA submission for COMP360 in treatment-resistant depression (TRD) underway; completion expected in the …

COMPASS Pathways plc Q2 2026: Revenue $0 Net loss $253.8M, EPS $(1.88) — 10-Q Summary

COMPASS Pathways plc reported a net loss of $253.8M, or diluted loss per share of $(1.88), for Q2 2026, with no product revenue as it remains a clinical-stage company. The company achieved positive primary endpoints in Phase 3 trials for treatment-resistant depression and advanced …

Compass Pathways (Nasdaq: CMPS) posts $253.8M Q2 loss and builds COMP360 launch

Compass Pathways reported a Q2 2026 net loss of $253.8 million, largely due to a non-cash loss from warrant liabilities, compared to $38.4 million in Q2 2025. Despite the widened loss, the company is making significant progress with its COMP360 psilocybin treatment for treatment-resistant …

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360's potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to …

Compass Pathways Launches Proposed $150.0 Million Public Offering

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced a proposed public offering of $150.0 million in American Depositary Shares (ADSs) and pre-funded warrants. The company may also grant underwriters an option to purchase an additional $22.5 million …

CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing

Compass Pathways PLC (CMPS) saw muted stock gains despite announcing positive 26-week data from its COMP360 trial for treatment-resistant depression, which confirmed the drug's rapid onset and durability. Analysts maintained "Buy" or "Outperform" ratings, emphasizing the long-term market opportunity and the drug's clean safety …

Compass Pathways PLC expected to post a loss of 40 cents a share - Earnings Preview

Compass Pathways PLC (CMPS) is projected to report a loss of 40 cents per share in its upcoming earnings announcement. This information is derived from a Refinitiv earnings preview. The full article can be accessed on TradingView, which aggregates news from various sources including …

Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS